Pfizer, a US-based drug company, is said to dismiss its merger deal with Allergan. The US drugmaker wants to quit from the $160 billion merger deal since Washington authorities set new rules, making corporate inversions harder.
Pfizer today confirmed that the company has increased the price of some of its drugs although it was not revealed how many drugs are involved with the price hike. According to a data by Wolters Kluwer which revealed that more than 100 types of drugs has been increased in its price starting on January 1st.
Subscribe to VCpost newsletter
- Vladimir Putin: Russia Becoming 'New Global Growth Center' Despite Western Isolation
- Investing Experts Say Now Is the Best Time to Invest in Small- and Midsize-Company Stocks — Here's Why
- Why Billionaire Tech Leader Romesh Wadhwani Is Investing $1 Billion on AI's Future
- Swiss Bank Banque Pictet Admits to Conspiring With US Taxpayers to Hide Over $5.6 Billion From IRS
- Maximizing Social Security Retirement Benefits: Experts Reveal Strategies to Get Bigger Monthly Checks
- Elon Musk's AI Startup X.AI Seeks to Raise $1 Billion From Equity Investors
- US Economy Is Still Robust With Labor Market Adding 199,000 Jobs in November
- Amazon Removes Venmo as Payment Method, Causing PayPal Shares to Drop